Equity Research Biotechnology

Should You Buy Lakewood-Amedex Biotherapeutics, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 0/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Lakewood-Amedex Biotherapeutics, Inc. (LABT) sits in the bottom tier of our quality coverage with a score of 3.4/10. While a weak quality score suggests operational challenges, our valuation models assess if the market has over-discounted the stock at $2.49.

The short answer: 0 of 0 CirclFi valuation models project upside for Lakewood-Amedex Biotherapeutics, Inc. (LABT) at $2.49 — the models are evenly split, with a Quality Score of 3.4/10 and Value-Trap risk of 0/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • Models are split: 0 bullish vs 0 bearish
  • Quality Score: 3.4/10 — Weak — below-average fundamentals
  • Value Trap Risk: 0/100 — Minimal — healthy fundamentals
  • Fair Value Range: — – —

Bullish Models

0 / 0

Bearish Models

0 / 0

Quality Score

3.4 /10

Weak — below-average fundamentals

Value Trap Risk

0 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

0 /13
Active Models

Full institutional coverage

What Is the Investment Case for Lakewood-Amedex Biotherapeutics, Inc. (LABT) in 2026?

What Is the Bull Case vs the Bear Case for Lakewood-Amedex Biotherapeutics, Inc. (LABT)?

Bull case versus bear case for Lakewood-Amedex Biotherapeutics, Inc. (LABT) at $2.49, derived from 0 active CirclFi valuation models on 2026-08-27.
Bull case Bear case
No active model projects meaningful upside for LABT at $2.49. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. No active model flags significant downside for LABT. The low Value Trap score paints a constructive picture.

How Does LABT Compare to Its Biotechnology Peers?

KLRA Kailera Therapeutics
3.4
AVLN Avalyn Pharma Inc.
3.4
ADTX Aditxt, Inc.
3.4
CNXU Conexeu Sciences Inc
3.4
KARD Kardigan, Inc.
3.5
TRAX First Tracks Biother
3.4
VTGN Vistagen Therapeutic
6.3
ALXO ALX Oncology Holding
5.2

Valuation data pages: KLRA · AVLN · ADTX · CNXU · KARD · TRAX · VTGN · ALXO · CGTX · EXEL · INCY

See full Biotechnology rankings →

Which Other Stocks Score Like LABT on Quality?

Closest companies to LABT’s Quality of Company score of 3.4/10, across all industries.

Which Biotechnology Screens Does LABT Appear In?

Why Do CirclFi’s 0 Models Disagree on LABT?

What Are the Biggest Risks of Buying LABT Stock?

Weak Fundamentals

QOC 3.4/10 signals below-average quality.

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View LABT Data Page →

So Is Lakewood-Amedex Biotherapeutics, Inc. (LABT) Worth Buying in 2026?

Lakewood-Amedex Biotherapeutics, Inc. currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.

These are quantitative model outputs, not investment recommendations. Lakewood-Amedex Biotherapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About LABT Stock?

Should I buy LABT stock right now?

Based on CirclFi's multi-model analysis, 0 of 0 models see upside for LABT at $2.49. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Lakewood-Amedex Biotherapeutics, Inc.?

Key risks include: a below-average Quality Score of 3.4/10, indicating fundamental weakness; limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does LABT compare to its competitors?

Among Biotechnology peers, LABT holds a Quality Score of 3.4/10. Comparable companies include KLRA (QOC 3.4), AVLN (QOC 3.4), ADTX (QOC 3.4). The relative ranking helps investors identify whether LABT offers better fundamental quality than alternatives in the same sector.

Is LABT a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. LABT's Quality Score of 3.4/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy LABT at?

CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for LABT.

View LABT Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →